A person’s “bioenergetic age”, or how youthfully their cells generate energy, might be a key indicator of whether they’re at ...

A person's 'bioenergetic age' -- or how youthfully their cells generate energy -- might be a key indicator of whether they're at risk of developing Alzheimer's disease, new research shows. The study ...

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to such cells in non-immunized controls, regardless of whether the treatment was ...

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they slowed the progression of memory-robbing illness in its early stages by up to 35 ...

The National Institute for Health and Care Excellence (NICE) has decided to reconsult on draft guidance for Alzheimer’s treatments donanemab and lecanemab, six months after initially rejecting the ...

Researchers from the Drug Safety Research Unit are calling for the robust monitoring of the safety of lecanemab, a promising new drug to treat Alzheimer’s Disease (AD). In a review article, published ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. Today we’ve published further draft guidance for public consultation that continues to not recommend ...

Bioenergetic age, or how efficiently cells produce energy, could predict Alzheimer’s risk, with healthy lifestyle choices ...